To validate our data and observe the variation of CHI3L1 and other biomarkers throughout the disease course, further longitudinal and multicentre studies with a higher number of patients both in the MND and MND mimics groups are needed. The gene discussed is CHI3L1; the disease is mild neurocognitive disorder.